Key facts
- This page summarizes RA CAPITAL MANAGEMENT, L.P.'s Form 4 filing for Adicet Bio, Inc. (ACET).
- 2 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 29 Apr 2026, 16:15.
RA CAPITAL MANAGEMENT, L.P. - 27 Apr 2026 Form 4 Insider Report for Adicet Bio, Inc. (ACET)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ACET
- Reported as of
- 27 Apr 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Apr 2026, 16:15:10 UTC
- Prior SEC filing
- 23 Apr 2026
- Next SEC filing
- 29 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
RA CAPITAL MANAGEMENT, L.P. filed Form 4 for Adicet Bio, Inc. (ACET) on 29 Apr 2026.
Change
- Previous filing in this sequence was filed on 23 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (4)
CIK 0001346824
Primary reporting owner
RA CAPITAL MANAGEMENT, L.P.
- Relationship
- 10%+ Owner
- Address
- C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON
- Signature
- /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
- Signature date
- 29 Apr 2026
CIK 0001315082
RA Capital Healthcare Fund LP
- Relationship
- 10%+ Owner
- Address
- C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON
- Signature
- /s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.
- Signature date
- 29 Apr 2026
CIK 0001384859
Kolchinsky Peter
- Relationship
- 10%+ Owner
- Address
- C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON
- Signature
- /s/ Peter Kolchinsky, individually
- Signature date
- 29 Apr 2026
CIK 0001619841
Shah Rajeev M.
- Relationship
- 10%+ Owner
- Address
- C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON
- Signature
- /s/ Rajeev Shah, individually
- Signature date
- 29 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACET
transaction
Common Stock
Other
- Transaction value
- Shares
- -250,000
- Change %
- -21%
- Price
- Shares after
- 932,624
- Date
- 27 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
ACET
transaction
Common Stock
Other
- Transaction value
- Shares
- -250,000
- Change %
- -21%
- Price
- Shares after
- 932,624
- Date
- 27 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
ACET
transaction
Common Stock
Other
- Transaction value
- Shares
- -250,000
- Change %
- -21%
- Price
- Shares after
- 932,624
- Date
- 27 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
ACET
transaction
Common Stock
Other
- Transaction value
- Shares
- -250,000
- Change %
- -21%
- Price
- Shares after
- 932,624
- Date
- 27 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACET
transaction
Derivative
Pre-Funded Warrant (Right to Buy)
Other
- Transaction value
- Shares
- +250,000
- Change %
- +22%
- Price
- Shares after
- 1,402,833
- Date
- 27 Apr 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $0.000100
- Footnotes
- F1, F2, F3, F4
ACET
transaction
Derivative
Pre-Funded Warrant (Right to Buy)
Other
- Transaction value
- Shares
- +250,000
- Change %
- +22%
- Price
- Shares after
- 1,402,833
- Date
- 27 Apr 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $0.000100
- Footnotes
- F1, F2, F3, F4
ACET
transaction
Derivative
Pre-Funded Warrant (Right to Buy)
Other
- Transaction value
- Shares
- +250,000
- Change %
- +22%
- Price
- Shares after
- 1,402,833
- Date
- 27 Apr 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $0.000100
- Footnotes
- F1, F2, F3, F4
ACET
transaction
Derivative
Pre-Funded Warrant (Right to Buy)
Other
- Transaction value
- Shares
- +250,000
- Change %
- +22%
- Price
- Shares after
- 1,402,833
- Date
- 27 Apr 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $0.000100
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
RA CAPITAL MANAGEMENT, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
On April 27, 2026, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 250,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 250,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (the "Pre-Funded Warrant").
Footnote F2
RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
Footnote F3
Held directly by the Fund.
Footnote F4
The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.